Literature DB >> 10748293

Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas.

M Suzuki1, S Saito, Y Saga, M Ohwada, I Sato.   

Abstract

The genetic etiology of serous and mucinous ovarian carcinomas was investigated in 76 affected patients, focusing on the possible loss of heterozygosity (LOH) involving chromosome band 6q27 and K-RAS mutations at codon 12. The incidence of LOH in 6q27 (6q27 LOH) was 41% in 64 informative cases; 53% (20/38) and 23% (6/26) in cases of serous ovarian carcinoma and in those of mucinous ovarian carcinoma, respectively, indicating that the incidence of 6q27 LOH was significantly higher in cases of serous ovarian carcinoma (P < 0.05). The incidence of K-RAS mutations at codon 12 was 23% (15/64); 5% (2/38) and 50% (13/26) in cases of serous ovarian carcinoma and in those of mucinous ovarian carcinoma, respectively, indicating that the incidence of the K-RAS mutations was significantly higher in cases of mucinous ovarian carcinoma (P < 0.0001). Thus, K-RAS mutations at codon 12 and 6q27 LOH were suggested to be involved in the development and/or progression of mucinous ovarian carcinoma and serous ovarian carcinoma, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10748293     DOI: 10.1016/s0165-4608(99)00192-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

Review 1.  Oligonucleotide treatment of ras-induced tumors in nude mice.

Authors:  E Wickstrom
Journal:  Mol Biotechnol       Date:  2001-05       Impact factor: 2.695

Review 2.  Microenvironment and pathogenesis of epithelial ovarian cancer.

Authors:  Antonio F Saad; Wei Hu; Anil K Sood
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

3.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.

Authors:  Sandra Orsulic; Yi Li; Robert A Soslow; Lynn A Vitale-Cross; J Silvio Gutkind; Harold E Varmus
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.